Research & Development

Moderna in talks with South Korea to supply 40 million doses of Covid-19 vaccine

Biotechnology company Moderna is negotiating with the South Korean government to potentially provide 40 million or more doses of its vaccine against Covid-19.

Aurobindo, COVAXX sign deal to develop Covid-19 vaccine UB-612

Aurobindo Pharma has signed an exclusive license agreement with US-based COVAXX to develop the latter’s UB-612 multitope peptide-based vaccine to fight Covid-19.

Hyundai Bioscience develops injection drug for potential treatment of severe cases of Covid-19

Hyundai Bioscience announced that CNPharm, its major shareholding bio tech company, has succeeded in developing 'Poly-COV01,' an injection drug for the potential treatment of patients with severe cases of Covid-19.

Servier to buy Agios’ oncology business for up to $2bn

Pharmaceutical company Servier has agreed to acquire oncology business from Agios Pharmaceuticals for up to $2bn.

Neurogene closes $115m series B financing

Neurogene, a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the completion of a $115m Series B financing.

Novartis to buy neuroscience firm Cadent Therapeutics for up to $770m

Swiss drugmaker Novartis has agreed to acquire US-based neuroscience company Cadent Therapeutics for a total potential consideration of $770m.

CN Bio, University of Melbourne collaborate to advance therapies for respiratory complications in recovered Covid-19 patients

CN Bio announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients.

Eli Lilly to buy gene therapy firm Prevail Therapeutics for $1.04bn

Eli Lilly has agreed to acquire US-based gene therapy company Prevail Therapeutics for an aggregate value of up to $1.04bn.

EQT IX offers to buy Swedish firm Recipharm for $2.1bn

Private investment organisation EQT IX has offered to acquire Swedish contract development and manufacturing organisation (CDMO) Recipharm for $2.1bn.